MAIA Biotechnology Inc. (MAIA)
MAIA Biotechnology Advances Ateganosine Cancer Treatment Program, Outlines Targeted 2026 Clinical Milestones and Growth Momentum
Apyx Medical Inc (APYX)
Valneva SE ADR (VALN)
PainReform Ltd. (PRFX)
Akanda Corp (AKAN)
Phio Pharmaceuticals Corp. (PHIO)
Phio Pharmaceuticals Announces Key Tumor Response Data from all Cohorts in Intratumoral PH-762 Dose Escalation Cutaneous Carcinoma Trial
Aurora Cannabis Inc. (ACB)
Aurora Secures EU Community Plant Variety Rights for Two Proprietary Cannabis Varieties
Illumina Inc (ILMN)
Illumina, Inc. - Illumina secures CMS reimbursement forTruSight™ Oncology Comprehensive, expanding access to precision oncology
Hillstream BioPharma Inc. (was rebranding to Tharimmune Inc (THAR)) (HILS)
Aytu BioPharma Inc. (AYTU)
Aytu BioPharma Highlights Opportunity for EXXUATM (gepirone) as New Way to Treat Major Depressive Disorder That Avoids Common Side Effects of Sexual Dysfunction and Significant Weight Gain following launch of EXXUA
RAPT Therapeutics Inc (RAPT)
Abbott Laboratories (ABT)
Abbott receives CE Mark for the TactiFlex™ Duo Ablation Catheter to treat patients with abnormal heart rhythms
Tharimmune Inc (THAR)
Tharimmune, Inc. Announces Pricing of $55 Million Underwritten Registered Offering
Propanc Biopharma, Inc. (PPCB)
Propanc Biopharma Files New Provisional Patent Application for Methods of Producing Trypsinogen & Chymotrypsinogen with IP Australia